Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells

Leuk Lymphoma. 2015;56(8):2458-9. doi: 10.3109/10428194.2014.999329. Epub 2015 Jan 29.

Affiliations

¹ a IRCCS Referral Cancer Center of Basilicata, Rionero in Vulture , Potenza , Italy.
² b CEINGE Institute of Advanced Biotechnologies, University of Naples , Italy.

PMID: 25547653
DOI: 10.3109/10428194.2014.999329

No abstract available

Publication types

Letter

MeSH terms

Antigens, CD20 / genetics
Antigens, CD20 / metabolism*
Antineoplastic Agents / pharmacology*
Cell Membrane / metabolism*
Gene Expression Regulation, Leukemic / drug effects
Humans
Lenalidomide
Leukemia, Lymphocytic, Chronic, B-Cell / genetics
Leukemia, Lymphocytic, Chronic, B-Cell / metabolism*
Thalidomide / analogs & derivatives*
Thalidomide / pharmacology

Substances

Antigens, CD20
Antineoplastic Agents
Thalidomide
Lenalidomide